Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations

Do you understand the role of non-targetable driver mutations in the management of acute myeloid leukemia (AML)?

Credit available for this activity expires: 5/1/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/991353?ecd=bdc_podcast_libsyn_mscpedu